CTXR Citius Pharmaceuticals Inc
Price (delayed)
$0.849
Market cap
$7.3M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$5.77
Enterprise value
$6.36M
Citius is a late-stage specialty pharmaceutical company dedicated to the development and commercialization of critical care products, with a focus on anti-infectives and cancer care.
Highlights
CTXR's debt has shrunk by 52% YoY and by 22% QoQ
The EPS is up by 12% year-on-year and by 3.4% since the previous quarter
Citius Pharmaceuticals's quick ratio has shrunk by 99% YoY and by 67% QoQ
Citius Pharmaceuticals's equity has decreased by 23% YoY and by 7% QoQ
Key stats
What are the main financial stats of CTXR
Market
Valuations
Earnings
Shares outstanding
8.59M
Market cap
$7.3M
Enterprise value
$6.36M
Price to earnings (P/E)
N/A
Price to book (P/B)
0.1
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
Gross profit
$0
Operating income
-$42.69M
Net income
-$39.68M
EBIT
-$38.98M
EBITDA
-$38.77M
Free cash flow
-$26.79M
Per share
Balance sheet
Liquidity
EPS
-$5.77
EPS diluted
-$5.77
Free cash flow per share
-$3.58
Book value per share
$8.46
Revenue per share
$0
TBVPS
$14.86
Total assets
$120.7M
Total liabilities
$51.78M
Debt
$204,569
Equity
$65.41M
Working capital
-$26.48M
Debt to equity
0
Current ratio
0.41
Quick ratio
0.03
Net debt/EBITDA
0.02
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-38.3%
Return on equity
-54.2%
Return on invested capital
-58.8%
Return on capital employed
-51.4%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
CTXR stock price
How has the Citius Pharmaceuticals stock price performed over time
Intraday
-2.85%
1 week
-12.29%
1 month
-42.24%
1 year
-95.37%
YTD
-78.78%
QTD
-43.02%
Financial performance
How have Citius Pharmaceuticals's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$42.69M
Net income
-$39.68M
Gross margin
N/A
Net margin
N/A
The operating income fell by 10% YoY
The net income is down by 3.9% year-on-year
Growth
What is Citius Pharmaceuticals's growth rate over time
Valuation
What is Citius Pharmaceuticals stock price valuation
P/E
N/A
P/B
0.1
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS is up by 12% year-on-year and by 3.4% since the previous quarter
The price to book (P/B) is 94% lower than the 5-year quarterly average of 1.7 and 92% lower than the last 4 quarters average of 1.2
Citius Pharmaceuticals's equity has decreased by 23% YoY and by 7% QoQ
Efficiency
How efficient is Citius Pharmaceuticals business performance
CTXR's ROE is down by 25% YoY and by 8% from the previous quarter
The company's return on assets rose by 4.3% QoQ
The ROIC has grown by 3.1% YoY
Dividends
What is CTXR's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for CTXR.
Financial health
How did Citius Pharmaceuticals financials performed over time
Citius Pharmaceuticals's total assets is 133% higher than its total liabilities
Citius Pharmaceuticals's quick ratio has shrunk by 99% YoY and by 67% QoQ
Citius Pharmaceuticals's current ratio has shrunk by 92% YoY but it has increased by 2.5% QoQ
CTXR's debt is 100% lower than its equity
The debt to equity has plunged by 100% YoY
CTXR's debt has shrunk by 52% YoY and by 22% QoQ
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.